NCT05464810 - Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2022

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2027

Conditions

Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast CarcinomaHormone Receptor-Positive Breast CarcinomaInvasive Breast Carcinoma

Interventions

DRUG

Letrozole

Given PO

DRUG

Simvastatin

Given PO

Trial Locations (4)

30303

RECRUITING

Grady Healthcare System, Atlanta

30308

RECRUITING

Emory University Hospital Midtown, Atlanta

30322

RECRUITING

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

RECRUITING

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER